← Oncology Approval Tracker

FDA DECISION ·

Padcev + Keytruda

enfortumab vedotin-ejfv + pembrolizumab · Astellas Pharma / Merck

Accelerated approvalNew or expanded indicationBladder cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Dec 15, 2023

FDA Project Confirm ↗

APPROVED USE

What FDA approved

For locally advanced or metastatic urothelial carcinoma in patients unable to receive cisplatin-containing chemotherapy.

LAMPGEN ANALYSIS

Why it matters

The initial combination approval was limited to cisplatin-ineligible patients and preceded the broader December decision.

What research teams should watch

Document why cisplatin was unsuitable and cite the eligibility rules in effect for the historical action.

PRIMARY RECORDS

Sources